Safety Information
Wegovy Side Effects Explained: All Doses Including 7.2 mg
Quick Answer: Wegovy (semaglutide) most commonly causes nausea, vomiting, diarrhoea, constipation and stomach pain, particularly during dose escalation. At the 7.2 mg dose, gastrointestinal side effects may briefly return or intensify before settling — mirroring the pattern seen at earlier steps. Most side effects are mild to moderate and ease within four to eight weeks at each dose level. Serious side effects are rare but include pancreatitis and gallbladder disease. This guide explains every side effect, when to expect it and how to manage it.44%of patients report nausea in STEP trials
4–8 wksfor most GI side effects to ease at each dose level
2.4–7.2 mgavailable injectable maintenance dose range
About Wegovy
What Is Wegovy and Why Does It Cause Side Effects?
Wegovy is the brand name for semaglutide, a once-weekly injectable GLP-1 receptor agonist approved by the MHRA for weight management. It is available at standard doses up to 2.4 mg and at a higher-dose option of 7.2 mg for eligible patients. By mimicking the GLP-1 hormone, Wegovy reduces appetite, slows gastric emptying and influences reward pathways associated with food cravings. Most side effects arise directly from this mechanism — slowed gastric emptying in particular causes nausea, bloating and discomfort, while GLP-1 receptor stimulation in the brain's nausea centres adds a neurological component. The structured dose escalation schedule is designed to reduce side effect severity by allowing the body to adapt at each step before proceeding to the next.
Common Side Effects (STEP Trial Data)
Side Effects by Dose Step
| Side Effect | Frequency (STEP Trials) | Typical Onset |
|---|---|---|
| Nausea | ~44% | Weeks 1–4 and at each dose step |
| Diarrhoea | ~30% | Weeks 1–6 |
| Vomiting | ~24% | Weeks 1–4 |
| Constipation | ~24% | Weeks 2–8 |
| Abdominal pain | ~20% | Weeks 1–8 |
| Headache | ~14% | Weeks 1–3 |
| Fatigue | ~11% | Weeks 1–6 |
| Indigestion / bloating | ~9% | Variable |
| Dizziness | ~7% | Variable |
| Dose | Reported Nausea (approx.) | Typical Pattern |
|---|---|---|
| 0.25 mg | ~30% | Mild; most patients tolerate well |
| 0.5 mg | ~38% | Mild to moderate; first significant step for some |
| 1.0 mg | ~44% | Peak nausea period for most patients |
| 1.7 mg | ~41% | Beginning to ease; appetite markedly reduced |
| 2.4 mg | ~20–25% | Substantially eased; maintenance equilibrium |
| 7.2 mg | ~25–30% transiently | Brief return on escalation then easing within 2–3 weeks; some patients report tingling or unusual skin sensations at this dose |
The 1.0 mg and 1.7 mg steps: These are most commonly associated with the highest side effect burden. Many patients find that nausea actually decreases once they reach the 2.4 mg maintenance dose — the body has had 16–20 weeks to adapt and the absence of further increases allows symptoms to stabilise.
Week-by-Week Timeline
| Period | What to Expect |
|---|---|
| Weeks 1–4 (0.25 mg) | Nausea most common, peaking around injection day and easing over 48 hours. Mild stomach discomfort and occasional loose stools are normal. Most patients manage well at this step. |
| Weeks 5–8 (0.5 mg) | Dose escalates. Nausea may temporarily increase. Constipation becomes more common as gastric emptying slows. Headache and fatigue possible. |
| Weeks 9–12 (1.0 mg) | Appetite suppression pronounced. GI symptoms often begin to settle. Peak nausea period for many patients at this step. |
| Weeks 13–16 (1.7 mg) | Nausea may briefly return. Rapid weight loss acceleration often begins here. Nutrition management important. |
| Week 17+ (2.4 mg) | Maintenance dose reached. Side effects substantially reduced for most patients. Nausea becomes infrequent. |
| Week 21+ (7.2 mg) | Optional higher dose. GI side effects may temporarily return, mirroring earlier escalation steps. Typically ease within 2–3 weeks. Some patients notice tingling or unusual skin sensations — more common at this dose. |
Patient note: If side effects at any stage are intolerable, speak to your prescribing pharmacist or clinician before adjusting your dose. Happy Pharmacy's clinical team is available throughout your treatment.
Managing Side Effects
How to Manage Nausea and GI Side Effects
Less Common Side Effects
🍽️ Dietary Strategies
Eat smaller, more frequent meals — three to four small meals daily. Avoid fatty, spiced, heavily processed or very sweet foods during dose escalation. Choose bland, easily digestible foods during flare-ups: plain rice, toast, boiled chicken, bananas. Eat slowly and stop before you feel full.
💧 Hydration
Aim for 2–3 litres of water daily. Small, frequent sips are easier to tolerate. Ginger tea and peppermint tea may help nausea. Avoid carbonated drinks which worsen bloating. Stay especially hydrated during diarrhoea episodes.
💉 Injection Timing
Some patients inject in the evening so peak side effects occur overnight. Consistency in day and time matters more than the specific choice. Select a day you can maintain reliably week to week.
📞 When to Seek Support
If nausea substantially affects quality of life or prevents adequate nutrition, contact your prescribing pharmacist. A temporary dose pause or slower escalation schedule is a recognised clinical approach. Over-the-counter antiemetics should be discussed with a pharmacist before use.
| Side Effect | Notes |
|---|---|
| Injection site reactions | Redness, bruising or mild swelling. Rotating injection sites across abdomen, thigh and upper arm reduces frequency. |
| Hair thinning (telogen effluvium) | Temporary shedding linked to rapid weight loss and calorie restriction rather than semaglutide directly. Usually resolves within six months. |
| Increased heart rate | A small increase (~2–4 bpm) observed in trials. Not clinically significant for most patients. |
| Acid reflux / GERD | Slowed gastric emptying can worsen reflux. Smaller meals and avoiding lying flat after eating helps. |
| Tingling / skin sensations | More commonly reported at the 7.2 mg dose. Usually transient. Mention to your prescribing team if persistent or troublesome. |
| Mood changes | Some patients report mood improvements as weight loss progresses. Rare reports of low mood — discuss with your clinician if concerned. |
Safety
Serious Side Effects — When to Seek Urgent Help
⚠ Seek urgent medical attention for any of the following
Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always disclose full thyroid and medical history before starting treatment.
| Symptom | Action |
|---|---|
| Severe, persistent abdominal pain radiating to the back | Stop Wegovy and seek urgent attention — possible pancreatitis |
| Upper right abdominal pain after eating; fever; jaundice | Contact GP — possible gallbladder disease |
| Swelling of face, lips, tongue or throat; difficulty breathing | Call 999 immediately — severe allergic reaction |
| Signs of dehydration: dizziness, dark urine, dry mouth | Seek medical attention and increase fluid intake urgently |
| Lump or swelling in the neck | Contact GP — should be assessed for thyroid abnormality |
| Significant mood change or depression | Contact GP or mental health professional |
Happy Pharmacy clinical support: All patients have access to our GPhC-registered pharmacist team (led by Superintendent Pharmacist Palvinder Deol) throughout treatment for side effect management, dose guidance and clinical review.
FAQs
Frequently Asked Questions: Wegovy Side Effects
The most common are nausea (~44%), diarrhoea (~30%), vomiting (~24%), constipation (~24%) and abdominal pain (~20%). These arise because semaglutide slows gastric emptying and activates GLP-1 receptors throughout the gut. Most are mild to moderate and ease significantly as the dose escalates and the body adapts.
For most patients, side effects are most pronounced during the first four to eight weeks and at each dose escalation step. By the maintenance dose of 2.4 mg — reached around week 17 — they have usually reduced substantially. Patients who escalate to 7.2 mg should expect a brief temporary recurrence which typically settles within two to three weeks.
The 1.0 mg and 1.7 mg steps are most commonly associated with the highest side effect burden. Many patients find that nausea actually decreases once they reach the 2.4 mg maintenance dose, as the body has had 16–20 weeks to adapt.
Yes, for the vast majority of patients. Nausea is most common during dose escalation and typically improves as the body adapts to each dose level. Eating smaller meals, avoiding fatty or spicy foods and staying well hydrated can significantly reduce nausea during the adjustment period.
A small proportion of patients notice temporary hair thinning. This is primarily attributed to rapid weight loss and calorie restriction (telogen effluvium) rather than to semaglutide directly. Hair growth typically returns within six months without specific treatment. Adequate protein intake throughout treatment can help.
Pancreatitis has been reported rarely with GLP-1 receptor agonists including semaglutide. Warning signs are severe, persistent abdominal pain radiating to the back, often with nausea and vomiting. If these symptoms occur, stop Wegovy and seek urgent medical attention. Patients with a history of pancreatitis should disclose this before starting.
If five or fewer days have passed since your scheduled dose, take it as soon as you remember. If more than five days have passed, skip it and resume on your usual day. Never take two doses in one week. Contact your Happy Pharmacy team if you have missed multiple doses.
At 7.2 mg, gastrointestinal side effects — nausea, diarrhoea, constipation — may temporarily return, mirroring the pattern seen at earlier escalation steps. This typically settles within two to three weeks. Some patients also report tingling or unusual skin sensations at this dose, which are more common at 7.2 mg than at lower doses. If GI symptoms are severe at 7.2 mg, returning to 2.4 mg is a clinically appropriate option.
Ready to Start Wegovy Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment · Superintendent Pharmacist: Palvinder Deol · Trustpilot 4.8 ★
Check Your Eligibility →
STEP 1. N Engl J Med. 2021. STEP UP (semaglutide 7.2 mg). Lancet Diabetes Endocrinol. 2025. Wegovy SmPC. Novo Nordisk. 2023/2025. NICE TA875. 2023. Happy Pharmacy (GPhC No. 9012585). Educational purposes only.